Health Care • Biotechnology: Pharmaceutical Preparations
$8.83 ▲ +0.03
(+0.34%)
MKT CAP: $308.1M • VOL: 162.5K
52W L $8 52W H $16
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
BNTC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$41.8M | -$22.5M | -$19.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$37.9M | -$21.8M | -$19.6M |
| EBITDA (Normalized) | -$41.8M | -$22.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$23.6M | -$19.4M | -$18.0M |
| Capital Expenditures (CapEx) | $18.0K | $179.0K | — |
| Free Cash Flow (FCF) | -$23.6M | -$19.6M | -$18.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $188.8M | $78.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $187.4M | $75.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BNTC.